Logo image of ALVAL.PA

VALBIOTIS SAS (ALVAL.PA) Stock Fundamental Analysis

EPA:ALVAL - Euronext Paris - Matif - FR0013254851 - Common Stock - Currency: EUR

1.1622  +0.04 (+3.21%)

Fundamental Rating

3

Overall ALVAL gets a fundamental rating of 3 out of 10. We evaluated ALVAL against 71 industry peers in the Biotechnology industry. The financial health of ALVAL is average, but there are quite some concerns on its profitability. While showing a medium growth rate, ALVAL is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ALVAL had negative earnings in the past year.
ALVAL had a negative operating cash flow in the past year.
In the past 5 years ALVAL always reported negative net income.
In the past 5 years ALVAL reported 4 times negative operating cash flow.
ALVAL.PA Yearly Net Income VS EBIT VS OCF VS FCFALVAL.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -5M -10M

1.2 Ratios

ALVAL has a Return On Assets (-34.58%) which is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -53.12%, ALVAL is in line with its industry, outperforming 54.93% of the companies in the same industry.
Industry RankSector Rank
ROA -34.58%
ROE -53.12%
ROIC N/A
ROA(3y)-32.59%
ROA(5y)-30.5%
ROE(3y)-63.5%
ROE(5y)-62.14%
ROIC(3y)N/A
ROIC(5y)N/A
ALVAL.PA Yearly ROA, ROE, ROICALVAL.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ALVAL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALVAL.PA Yearly Profit, Operating, Gross MarginsALVAL.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 -20K -40K -60K -80K

More info and screens

5

2. Health

2.1 Basic Checks

ALVAL does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALVAL has more shares outstanding than it did 1 year ago.
ALVAL has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ALVAL has an improved debt to assets ratio.
ALVAL.PA Yearly Shares OutstandingALVAL.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M
ALVAL.PA Yearly Total Debt VS Total AssetsALVAL.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

2.2 Solvency

An Altman-Z score of 1.87 indicates that ALVAL is not a great score, but indicates only limited risk for bankruptcy at the moment.
ALVAL has a better Altman-Z score (1.87) than 66.20% of its industry peers.
ALVAL has a Debt/Equity ratio of 0.24. This is a healthy value indicating a solid balance between debt and equity.
ALVAL has a Debt to Equity ratio of 0.24. This is in the better half of the industry: ALVAL outperforms 67.61% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.24
Debt/FCF N/A
Altman-Z 1.87
ROIC/WACCN/A
WACC7.43%
ALVAL.PA Yearly LT Debt VS Equity VS FCFALVAL.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5M -5M 10M 15M

2.3 Liquidity

ALVAL has a Current Ratio of 4.89. This indicates that ALVAL is financially healthy and has no problem in meeting its short term obligations.
ALVAL has a Current ratio of 4.89. This is amongst the best in the industry. ALVAL outperforms 81.69% of its industry peers.
A Quick Ratio of 4.54 indicates that ALVAL has no problem at all paying its short term obligations.
The Quick ratio of ALVAL (4.54) is better than 83.10% of its industry peers.
Industry RankSector Rank
Current Ratio 4.89
Quick Ratio 4.54
ALVAL.PA Yearly Current Assets VS Current LiabilitesALVAL.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 22.69% over the past year.
ALVAL shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -88.00%.
ALVAL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 126.73% yearly.
EPS 1Y (TTM)22.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-38.62%
Revenue 1Y (TTM)-88%
Revenue growth 3Y15.25%
Revenue growth 5Y126.73%
Sales Q2Q%-99.17%

3.2 Future

ALVAL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.03% yearly.
ALVAL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 33.49% yearly.
EPS Next Y-4.38%
EPS Next 2Y11.61%
EPS Next 3Y16.03%
EPS Next 5YN/A
Revenue Next Year-96.57%
Revenue Next 2Y-31.33%
Revenue Next 3Y23.74%
Revenue Next 5Y33.49%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ALVAL.PA Yearly Revenue VS EstimatesALVAL.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 5M 10M 15M
ALVAL.PA Yearly EPS VS EstimatesALVAL.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALVAL. In the last year negative earnings were reported.
Also next year ALVAL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALVAL.PA Price Earnings VS Forward Price EarningsALVAL.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALVAL.PA Per share dataALVAL.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

A more expensive valuation may be justified as ALVAL's earnings are expected to grow with 16.03% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.61%
EPS Next 3Y16.03%

More info and screens

0

5. Dividend

5.1 Amount

ALVAL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VALBIOTIS SAS

EPA:ALVAL (5/8/2025, 7:00:00 PM)

1.1622

+0.04 (+3.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-25 2025-04-25/amc
Earnings (Next)10-27 2025-10-27
Inst Owners2.75%
Inst Owner ChangeN/A
Ins Owners3.99%
Ins Owner ChangeN/A
Market Cap18.49M
Analysts85.45
Price Target3.67 (215.78%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-28.95%
PT rev (3m)-31.21%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-1.42%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-33.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 35.09
P/FCF N/A
P/OCF N/A
P/B 1.1
P/tB 1.18
EV/EBITDA N/A
EPS(TTM)-0.66
EYN/A
EPS(NY)-0.53
Fwd EYN/A
FCF(TTM)-0.48
FCFYN/A
OCF(TTM)-0.47
OCFYN/A
SpS0.03
BVpS1.06
TBVpS0.99
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -34.58%
ROE -53.12%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-32.59%
ROA(5y)-30.5%
ROE(3y)-63.5%
ROE(5y)-62.14%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.24
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.05%
Cap/Sales 41.37%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.89
Quick Ratio 4.54
Altman-Z 1.87
F-Score4
WACC7.43%
ROIC/WACCN/A
Cap/Depr(3y)37.37%
Cap/Depr(5y)34.99%
Cap/Sales(3y)61.06%
Cap/Sales(5y)102.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-38.62%
EPS Next Y-4.38%
EPS Next 2Y11.61%
EPS Next 3Y16.03%
EPS Next 5YN/A
Revenue 1Y (TTM)-88%
Revenue growth 3Y15.25%
Revenue growth 5Y126.73%
Sales Q2Q%-99.17%
Revenue Next Year-96.57%
Revenue Next 2Y-31.33%
Revenue Next 3Y23.74%
Revenue Next 5Y33.49%
EBIT growth 1Y-1.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-33.68%
EBIT Next 3Y17.23%
EBIT Next 5Y11.63%
FCF growth 1Y21.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.42%
OCF growth 3YN/A
OCF growth 5YN/A